Recently Viewed

  • Home
  • Stories
  • News Announcement
  • Eiko Lifesciences: Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March 2026 In Accordance With Regulation 33 Of The SEBI Listing Regulation.
News Announcement

Eiko Lifesciences: Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March 2026 In Accordance With Regulation 33 Of The SEBI Listing Regulation.

21-May-2026 Follow Value Research Online on Google download pdfDownload PDF Eiko Lifesciences

Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 inter alia to consider and approve The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on 31st March 2026 in accordance with Regulation 33 of the SEBI ListingRegulation.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.

These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan